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A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-directed scFv with a human IgG1 Fc
domain. Overexpression of the ErbB2 receptor is related to tumour aggressiveness and poor prognosis. This new immunoagent
meets all criteria for a potential anticancer drug: it is human, hence poorly or not immunogenic; it binds selectively and with high
affinity to target cells, on which it exerts an effective and selective antiproliferative action, including both antibody-dependent and
complement-dependent cytotoxicity; it effectively inhibits tumour growth in vivo. Its compact molecular size should provide for an
efficient tissue penetration, yet suitable to a prolonged serum half-life.
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Immunotherapy represents an effective strategy to fight cancer,
mainly based on antibodies specifically directed to selected cancer
cells (Trikha et al, 2002; Ross et al, 2003). Obstacles to full success
of present-day immunotherapy include: (i) immune responses
against non-human, or even humanised antibodies (Kuus-Reichel
et al, 1994); (ii) the large size of antibodies, which hinders their
diffusion into bulky tumours. Fully human, small-sized anti-
tumour immunoagents would overcome these risks, and provide
safe, highly selective and effective antitumour drugs.
A good candidate as a tumour-associated antigen, and an
attractive target for immunotherapy, is ErbB2 (also known as Her-
2/Neu), a transmembrane tyrosine kinase receptor, overexpressed
in breast carcinomas, for which it is a marker of poor prognosis
(Slamon et al, 1987). We recently isolated a novel human anti-
ErbB2 single-chain variable fragment (scFv) from a large phage-
display library (Griffin 1) through a double selection strategy
performed on live cells (De Lorenzo et al, 2002). This scFv, named
Erbicin, specifically binds to ErbB2-positive cells, inhibits the
receptor autophosphorylation, is internalised in target cells and
strongly inhibits their proliferation (De Lorenzo et al, 2002).
However, the small size of the scFv and its expected rapid
clearance from the bloodstream, as well as its monovalent nature,
could limit its use as a therapeutic agent selective for mammary
carcinoma cells.
A significant addition to the anticancer arsenal would be the
construction of a new anti-ErbB2 immunoagent from a human, per
se cytotoxic scFv and a human Fc domain. This fully human
antitumour antibody would be a compact, reduced version of an
IgG, with the antiproliferative effect of the scFv moiety on tumour
target cells, combined with the ability of the Fc moiety to induce
both antibody-dependent cellular cytotoxicity (ADCC) and com-
plement-dependent cytotoxicity (CDC). Yet, such a compact
antibody is expected to have (Demignot et al, 1990; Yokota et al,
1993; Powers et al, 2001) a more protracted half-life and higher
tumour retention than the parental scFv, but improved penetration
properties in solid tumours with respect to full-size IgG agents.
MATERIALS AND METHODS
Cell cultures and antibodies
The SKBR3 cell line from human breast cancer, the A431 cell line
from human epidermoid carcinoma, and Chinese hamster ovary
(CHO) cells (all from American Type Culture Collection, Rockville,
MD, USA) were cultured in RPMI 1640 (Gibco BRL, Life
Technologies, Paisley, UK). The TUBO cell line from a BALB-neu
T mouse-derived mammary lobular carcinoma (kindly provided
by Dr G Forni, University of Turin, Italy) was grown in DMEM
(Gibco BRL). The media were supplemented with 10% foetal
bovine serum (20% for TUBO cells), 50Uml
 1 penicillin, and
50mgml
 1 streptomycin (all from Gibco BRL).
The antibodies used were: Herceptin (Genentech, South San
Francisco, CA, USA); monoclonal anti-human IgG1 (Fc specific,
Sigma, St Louis, MO, USA); horseradish peroxidase-conjugated
goat anti-mouse immunoglobulins (Pierce, Rockford, IL, USA);
horseradish peroxidase-conjugated goat anti-human affinity-iso-
lated IgG (Fc specific) (Sigma).
Peripheral blood lymphocytes
Peripheral blood lymphocytes (PBL) were obtained from periph-
eral blood mononuclear cells (PBMC) isolated by centrifugation on
Lymphoprep gradients (Axis Shield PoC AS, Oslo, Norway) from
normal donor buffy coats obtained from the Blood Bank of the
Medical School of the University of Naples ‘Federico II’. After the
separation, PBL were washed twice and incubated in RPMI 1640
medium (Gibco BRL) for 2h at 371C to remove adherent cells. The
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any additional treatment.
Construction and production of the anti-ErbB2 Erb-hcAb
In a previous paper (De Lorenzo et al, 2002), we reported the
isolation of a novel human anti-ErbB2 scFv, selected by panning
the Griffin 1 phage library on live cells with a subtractive selection
strategy based on two combinations of ErbB2-positive and
-negative cell lines. The cDNA coding for the anti-ErbB2 scFv was
amplified from vector pHEN2 by PCR using as forward and reverse
primers oligonucleotides containing at their 50 end a HindIII site
and a BamHI site, respectively: (50-CCCCCCAAGCTTCAGGTG
CAGCTGTTG-30;5 0-AACCGCGGATCCGCACCTAGGACGGTCAG-
30). The PCR fragment was then digested with HindIII and BamHI
(New England Biolabs, Hertfordshire, UK) for cloning into the
corresponding sites in plasmid pIg1plus (R & D Systems,
Minneapolis, USA), downstream to the leader sequence and
upstream to the hinge-CH2-CH3 sequence, respectively, of a
human IgG1 heavy chain constant region (Fc).
The fusion protein was produced by transfecting CHO cells with
the recombinant vector. In brief, cells grown in RPMI containing
10% FCS at 70–80% confluency were transfected with 5mgo f
expression vector using the Superfect reagent (Qiagen, Valencia,
CA, USA). Stable transfectants were selected in the presence of
G418 (Sigma) at a concentration of 1mgml
 1. Expression of the
antibody construct was determined in the culture medium by
quantitative ELISA. For recombinant protein production, trans-
fected CHO cells were expanded to near confluence in selective
medium containing neomycin, and then were grown for 3–4 days
in serum-free medium.
The recombinant fusion protein, henceforth termed Erb-hcAb,
secreted by transfected CHO cells, was purified from culture
medium by affinity chromatography on a protein A-Ceramic
Hyper D
sF column (BioSepra, Cergy-Saint-Christophe, France)
loaded with 300–500ml of conditioned medium, washed with 10
volumes of 100mM Tris-HCl, pH 8.0 containing 0.5 M NaCl, and 10
volumes of 10mM Tris-HCl, pH 8.0. The protein eluate was
obtained with 50mM glycine pH 3.0, and immediately neutralised
with 1/10 volume of 1 M Tris-HCl, pH 8.0.
ELISA assays
ErbB2-positive SKBR3 cells and ErbB2-negative A431 control cells,
harvested in nonenzymatic dissociation solution (Sigma), were
washed and transferred to U-bottom microtitre plates (1 10
5cells
per well). After blocking with PBS containing 6% bovine serum
albumin (BSA), cells were incubated with conditioned medium or
purified immunoagents in ELISA buffer (PBS/BSA 3%) for 90min.
The pelleted cells were washed, resuspended in 100ml of ELISA
buffer, and incubated with an anti-human IgG (Fc-specific) mAb
(Sigma) or anti-myc mAb 9E10 (Evan et al, 1985), for detection of
Erb-hcAb and Erbicin (containing the myc tag), respectively. Goat
anti-mouse HRP-conjugated immunoglobulins (Pierce, Rockford,
IL, USA) were used for detection of bound antibodies. After 1h,
the plates were centrifuged, washed with ELISA buffer, and reacted
with 3,30,5,50-tetramethylbenzidine (TMB) (Sigma). Binding values
were determined from the absorbance at 450nm, and reported as
the mean of at least three determinations (s.d. p5%).
Cell growth inhibition assays
Cells were seeded in 96-well, flat-bottom plates; SKBR3 and TUBO
cells at a density of 1.5 10
4well; A431 at a density of 5 10
3well.
After addition of the protein under test viable cells by the Trypan
blue-exclusion test were counted at suitable time intervals. Cell
survival was expressed as percent of viable cells in the presence of
the protein under test with respect to control cultures grown in the
absence of the protein. Typically, cell survival values were obtained
from at least three separate experiments in which triplicate counts
were determined; standard deviations were below 5%.
ADCC and CDC tests
Target and control cells were detached from culture dishes with a
cell dissociation solution (Sigma) and transferred to round-bottom
96-well plates (2 10
4cells per well). For ADCC assays, target or
control cells were treated with the immunoagents (3mgml
 1 of
serum-free medium) and peripheral blood lymphocytes (PBL) at
371C for 3–4h. For CDC assays, cells were incubated at 371C with
human serum. Cultures were performed in triplicate in a final
volume of 200ml. Controls included target cells incubated in the
absence of effector, or in the presence of either serum or
immunoagent alone. Tumour cell lysis was determined by
measuring the release of lactate dehydrogenase (LDH) using a
LDH detection kit (Roche, Mannheim, Germany). ADCC or CDC
were calculated as the percent of cytolysis measured in the
presence of immunoagent and PBL or human serum, for ADCC
and CDC, respectively, taking as 100% the maximal LDH release
determined by lysis of target cells with 1% Triton X-100.
In vivo antitumour activity
All experiments were performed with 6-week-old female Balb/
cAnNCrlBR mice (Charles River Laboratories, Calco, Italy). TUBO
cells (5 10
5) were suspended in 0.2ml sterile PBS and injected
subcutaneously (day 0) in the right paw. At day 7, when tumour
started to appear, the mice were divided into two groups. At day
15, when tumours were clearly detectable, Erb-hcAb dissolved in
PBS was administered at a site remote from that of tumour
implantation, at doses of 2.5mgkg
 1 of body weight for 7 times at
72h intervals. The second group of control animals was treated
with identical volumes of sterile PBS. During the period of
treatment, tumour volumes (V) were measured with caliper and
calculated by the formula of rotational ellipsoid V¼A B
2/2 (A is
the axial diameter, B the rotational diameter). All mice were
maintained at the animal facility of the Department of Cellular and
Molecular Biology and Pathology, University of Naples Federico II.
Animal studies were conducted in accordance with the Italian
regulation for experimentation on animals. All in vivo experiments
were carried out with ethical committee approval and met the
standards required by the UKCCCR guidelines (Workman et al,
1998).
RESULTS
Construction and characterisation of a human anti-ErbB2
compact antibody
We generated a new anti-ErbB2 immunoagent by fusing the scFv
Erbicin with a human IgG1 Fc domain. The IgG-like protein has a
reduced molecular weight, and contains all functionally relevant
antibody regions. The cDNA coding for the human anti-ErbB2
scFv was amplified by PCR and cloned into a eukaryotic
expression vector containing the human IgG1 Fc sequence. The
recombinant plasmid, sequenced to confirm faithful cloning, was
stably transfected in Chinese hamster ovary cells, and expressed as
a secretion product into the culture medium. After purification by
affinity chromatography, the final yield of the fusion protein was
1.5mgl
 1. The immunoagent was named Erb-hcAb (anti-ErbB2
human compact antibody). When Erb-hcAb was analysed by SDS–
PAGE (Figure 1), it was found to migrate under reducing
conditions with the expected molecular size of about 50kDa, and
as a dimer of about 100kDa under nonreducing conditions. This
indicated that the fusion protein is expressed as a disulphide-
linked dimer. Western blotting analysis performed with an
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purified, dimeric protein with 100kDa size (Figure 1).
When the ability of the recombinant fusion protein to bind
ErbB2-positive cells was analysed by ELISA assays (Figure 2A),
Erb-hcAb was found to fully retain the specificity of the original
scFv for mammary carcinoma SKBR3 ErbB2-overexpressing cells.
It did not react instead with ErbB2-negative cells such as A431 cells
(from human epidermoid carcinoma), which overexpress the
ErbB1 EGF receptor from the same ErbB family. The apparent
binding affinity of the compact antibody for the ErbB2 receptor,
that is, the concentration corresponding to half-maximal satura-
tion, was about 1nM, comparable to the values of 4 and 5nM,
determined for the parental scFv, and Herceptin, a humanised
anti-ErbB2 monoclonal, respectively (see Figure 2A). Presumably,
the four-fold increased avidity with respect to Erbicin is due to the
acquired bivalency of Erb-hcAb for ErbB2.
Biological effects of Erb-hcAb on ErbB2-positive tumour
cells
The effect of Erb-hcAb on tumour cell growth was assessed by
measuring the survival of SKBR3 cells treated with increasing
concentrations of Erb-hcAb. As shown in Figure 2B, the anti-ErbB2
Erb-hcAb inhibited the growth of SKBR3 cells in a dose-dependent
fashion, with an antiproliferative effect more pronounced than that
observed for Herceptin, and no effects on the proliferation of
ErbB2-negative A431 cells (see Figure 2B).
To investigate whether Erb-hcAb was capable of recruiting
immune effector functions in vitro, assays for cytolysis of tumour
cells as induced by PBL, or complement, were performed. To
determine the capacity of Erb-hcAb to trigger ADCC towards
antigen-expressing cells, ErbB2-positive and ErbB2-negative con-
trol cells were incubated for 3h with increasing amounts of effector
PBL in the absence or in the presence of Erb-hcAb (3mgml
 1). As
shown in Figure 3A, Erb-hcAb effectively lysed SKBR3 target cells
in the presence of PBL. The extent of lysis reached almost 100% of
treated cells, whereas Herceptin, used as a positive control,
induced about 60% lysis. The basal level of cytotoxicity was
measured in the presence of PBL (see Figure 3A) or Erb-hcAb
alone (data not shown). No effects were detected in parallel assays
carried out with ErbB2-negative cells, such as A431 (data not
shown), or when Erb-hcAb was replaced by the parental anti-
ErbB2 scFv, lacking the Fc domain (see Figure 3A). These results
indicate the specificity of the Erb-hcAb-dependent cell-mediated
cytolytic activity, clearly based on both binding abilities of the
immunoagent: (i) to the cognate receptor with its antigen binding
sites; (ii) to natural killer cells with its Fc effector domain.
To test the ability of Erb-hcAb to induce CDC against ErbB2-
positive tumour cells, SKBR3 target cells were incubated for 2 or
6h with Erb-hcAb (at 3 or 10mgml
 1 concentrations) in the
absence or the presence of human serum as a source of
complement. As illustrated in Figure 3B, Erb-hcAb was found to
effectively lyse SKBR3 cells in the presence of serum, with an
average specific lysis of 50% after 2h, increased to about 70% after
additional 4h of incubation with 10mgml
 1 of Erb-hcAb (see
Figure 3B). Heat inactivation of serum completely abolished the
complement-dependent lysis. Moreover, CDC was not detected
when ErbB2-negative A431 cells were incubated with Erb-hcAb
and human serum (data not shown). Similarly, as expected
(Drebrin et al, 1988), no lysis was detectable when SKBR3 cells
were treated with Herceptin in the presence of human serum (see
Figure 3B).
In vivo antitumour activity of Erb-hcAb
For in vivo studies, Erb-hcAb was tested on murine TUBO tumour
cells expressing ErbB2 of rat origin (Rovero et al, 2000). In vitro,
TUBO cells were found to be sensitive to the treatment with Erb-
hcAb with an IC50 of 0.5mM. This indicated cross-reactivity
between the human immunoagent and rat ErbB2 (Rovero et al,
13 4
100 kDa
50 kDa
2
Figure 1 SDS–PAGE of purified Erb-hcAb. Erb-hcAb was run under
reducing (lane 2) and nonreducing (lane 3) conditions. Lane 4: Western
blot analysis of the sample run in lane 3 tested with an anti-human IgG1 (Fc
specific) antibody. Molecular weight standards are in lane 1.
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Figure 2 Effects of Erb-hcAb on ErbB2-positive (SKBR3) and ErbB2-
negative (A431) cells. (A) ELISA assays of SKBR3 cells (black symbols) and
A431 cells (empty symbols) tested with Erb-hcAb (circles), the parental
anti-ErbB2 scFv (rhomboids), or Herceptin (squares). (B) Dose–response
curves for ErbB2-positive SKBR3 cells (black symbols), or ErbB2-negative
A431 cells (empty symbols), treated for 72h with Erb-hcAb (circles), or
Herceptin (squares).
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homologs are highly superimposable (Cho et al, 2003).
When administered to mice, TUBO cells induce tumours very
similar to the alveolar-type human lobular mammary carcinomas
(Di Carlo et al, 1999). As shown in Figure 4, the treatment of mice
bearing TUBO tumours with seven doses, at 72h intervals, of
2.5mgkg
 1 of Erb-hcAb induced a dramatic reduction (96%) in
tumour volume. During the period of treatment, the animals did
not show signs of wasting or other visible signs of toxicity.
DISCUSSION
The results described in this report show that the Erb-hcAb
immunoagent has a high therapeutic potential, as it fully satisfies
the conditions required for a successful anticancer agent: it is a
fully human immunoagent, hence presumably with a reduced or
no immunogenicity; it recognises with high affinity one of the most
specific tumour-associated antigens, such as ErbB2; it displays
effective antibody effector functions; it is effective in inhibiting
target cell growth both in vitro and in vivo. Furthermore, its size
should be better suited to therapeutic applications than either a
small scFv, or full-size IgG-like molecules.
Previous reports have shown the feasibility of cloning single-
gene constructs encoding fusion proteins made up of murine scFv
and Fc fragments (Shu et al, 1993; Li et al, 2000; Xu et al, 2000).
Recently, a recombinant, human scFv-Fc antibody has been
reported (Powers et al, 2001) to mediate in vitro ADCC and
endure a much longer serum half-life in vivo when compared to its
parental scFv. However, the protein was produced in yeast with
yeast-controlled glycosylation; furthermore, it was found to be
heterogeneous, obtained in very low yields, and only partially
glycosylated. It should be noted that Erb-hcAb, as reported above,
was prepared instead in CHO cells, a mammalian model certainly
closer than yeast to human cells.
Herceptin, currently used for treatment of advanced breast
cancer (Baselga et al, 1999; Stebbing et al, 2000), is a humanised
version of a murine anti-ErbB2 antibody. Its antitumour activity is
mostly based on its ability to downregulate ErbB2 and induce
ADCC (Sliwkowski et al, 1999), but, as previously reported
(Drebrin et al, 1988), it does not elicit CDC. The new immunoagent
Erb-hcAb instead displays a strong CDC effect, and has a reduced
molecular size (100kDa) with respect to that of Herceptin
(155kDa). It has been shown (Demignot et al, 1990; Yokota et al,
1993; Powers et al, 2001) that in an immunoagent of about 100kDa
the advantage of the prolonged half-life of an intact antibody is
composed with an increased extravascular diffusion, both very
expedient features for targeting solid tumours.
Taken together, the data reported here suggest that Erb-hcAb is
a promising new anticancer agent, and supports the concept that,
after humanised monoclonals and scFvs, a third generation of
immunoagents, human compact antibodies, may represent the
format of choice for the therapy of solid tumours.
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Figure 4 In vivo suppression of tumour growth by Erb-hcAb. Tumour
growth was followed in mice inoculated s.c. with 5 10
5 TUBO mammary
carcinoma cells. Control animals (black circles) were treated with sterile
PBS solution. Treated animals (white circles) were injected with Erb-hcAb,
starting at day 15. Seven doses, each of 2.5mgkg
 1 of body weight, were
administered at 72h intervals.
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Figure 3 Antibody-dependent and complement-dependent cytotoxicity
assays of Erb-hcAb. (A) SKBR3 cells treated with PBL as effector cells at
four different ratios: in the absence (white bars), or in the presence of Erb-
hcAb (black bars). Erbicin, the parental anti-ErbB2 scFv (striped bars), and
Herceptin (grey bars) were used as a negative and a positive control,
respectively. (B) ErbB2-overexpressing SKBR3 cells were incubated for 2
or 6h, in the presence of human serum as a source of complement, with
Erb-hcAb at a concentration of 3mgml
 1 (shaded bars) or 10mgml
 1
(black bars). Herceptin (10mgml
 1) was used as a negative control (white
bars).
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